Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Gilead said its fourth-quarter HIV product sales rose to $5.45 billion from $4.69 billion a year earlier, due to higher ...

BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

Gilead KOA Holiday has been recognized with the prestigious KOA ICON Award. This recognition highlights campgrounds that demonstrate exceptional operational excellence, customer satisfaction, and a ...